This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Heterozygous Familial Hypercholesterolemia (HEFH) Management Market

Market Insights on Heterozygous Familial Hypercholesterolemia (HEFH) Management covering sales outlook, demand forecast & up-to-date key trends

Heterozygous Familial Hypercholesterolemia (HEFH) Management Market by Product Type, Application & Region | Forecast 2023 to 2033

Heterozygous Familial Hypercholesterolemia (HEFH) Management Market Snapshot (2023 to 2033)

The global heterozygous familial hypercholesterolemia (HEFH) management market is expected to be worth US$ 15.11 Billion in the fiscal year 2023, which rose up from US$ 13.2 Billion in the fiscal year 2022. From 2023 to 2033, the global market is expected to grow at a 14.5% CAGR, reaching a value of US$ 58.54 Billion by the end of 2033.

Familial hypercholesterolemia (FH) is a hereditary disorder that results in high levels of low-density lipoprotein (LDL) cholesterol (also known as bad cholesterol) from birth. FH stands for familial hypercholesterolemia. FH is caused by unique DNA alterations that are handed down from one generation to the next. It is not caused by elements in one's lifestyle, including a high-fat diet or even a lack of exercise.

Without therapy, HEFH causes exceedingly high LDL as well as total cholesterol levels. Excess LDL cholesterol can clump together and create plaque in the artery walls. The plaque constricts the arteries, allowing less blood to flow through them. This is referred to as artery hardening. Whenever this happens, the heart must exert more effort to circulate blood throughout the body.

The heart can be damaged over time, resulting in heart disease. If this occurs, one of the primary symptoms is chest discomfort known as angina. This could result in a heart attack or even stroke if not treated. Thus, this disease needs to be treated at the earliest, and such reasons are why there is a surge in demand within the Heterozygous Familial Hypercholesterolemia (HEFH) management market globally.

Data Points

Key Statistics

Anticipated Base Year Value (2022)

US$ 13.2 Billion

Expected Market Value (2023)

US$ 15.11 Billion

Projected Forecast Value (2033)

US$ 58.54 Billion

Global Growth Rate (2023 to 2033)

14.5%

CAGR of North America (2023)

15.3%

CAGR of Europe (2023 to 2033)

14%

Customize this Report

Let us know your requirement to get
100% FREE customization

2018 to 2022 Heterozygous Familial Hypercholesterolemia (HEFH) Management Market Demand Analysis Vs. Forecast 2023 to 2033

The global heterozygous familial hypercholesterolemia (HEFH) management Market grew at a CAGR of 9.2% from 2018 to 2022, as per Future Market Insights, a provider of market research and competitive intelligence. The prevalence of chronic illnesses and cardiovascular diseases, as well as an increase in the number of clinical trials along with research studies for the management of heterozygous familial hypercholesterolemia, are major drivers of the market's revenue growth. The current explosive growth of clinical medication innovation for hypercholesterolemia is another factor that is projected to fuel market revenue growth.

Due to technological advancements in the treatment of heterozygous familial hypercholesterolemia, enhanced healthcare facilities, greater research and drug development for the diagnosis, government initiatives to raise public awareness of the symptoms, causes, and therapeutic options for this type of hypercholesterolemia, as well as increased healthcare investments, it is predicted that the market will experience abundant opportunities for growth during the forecast period.

Such factors are expected to boost the global sales of Heterozygous Familial Hypercholesterolemia (HEFH) management solutions. As a result, the global Heterozygous Familial Hypercholesterolemia (HEFH) Management Market is expected to forecast a CAGR of over 14% from 2023 to 2033.

Prominent Growth Drivers Influencing Heterozygous Familial Hypercholesterolemia (HEFH) Management Market

Unhealthy Lifestyles and Aging Population to Boost Demand

One of the main factors fueling the market's expansion is the increased prevalence of HEFH brought on by the general public's increasingly unhealthy lifestyle. This is supported by the growing geriatric population, which is vulnerable to cardiovascular illnesses (CVDs) and a number of other chronic diseases, including diabetes, renal troubles, and thyroid issues.

Additionally, other growth-promoting variables include the growing interest in health and the understanding of the many treatment options for HEFH management. Such factors are sure to propel the market for Heterozygous Familial Hypercholesterolemia (HEFH) management during the forecast period.

Increasing Research and Development and New Product Launches to accelerate Market Expansion

The launch of numerous medications and treatments to help hypercholesterolemia patients reach near-normal lipid profiles and lower their risk of developing CVD is giving market growth a significant boost. In addition, the creation of new medication classes with improved effectiveness and safety profiles is boosting market expansion. The introduction of numerous combination medicines to treat hypercholesterolemia that also contain other cholesterol-lowering substances is also contributing to the market's expansion.

In addition, the statins' widespread use is promoting market expansion due to their numerous benefits, including improved endothelial function, reduced oxidative stress-induced cell damage, higher atherosclerotic plaque stability, and lower inflammation. Such developments are expected to accelerate the demand for Heterozygous Familial Hypercholesterolemia (HEFH) management during the forecast period.

Sabyasachi Ghosh
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What Could Possibly Hinder Heterozygous Familial Hypercholesterolemia (HEFH) Management Market Demand?

Lack of Awareness and Knowledge to Impede Expansion

Both healthcare professionals and the general population are unaware of FH. As a result, it receives insufficient attention and care. Untreated HEFH patients have a 20x higher risk of developing coronary artery disease than HEFH-free individuals.

Heart attacks, stroke, and sudden cardiac death are all important cardiovascular disorders that can be brought on by coronary artery disease. However, this risk can be decreased with an early diagnosis with universal lipid screening, cascade screening in families, and effective treatment using statins and other drugs.

Region-wise Analysis

What is the outlook of the North American Heterozygous Familial Hypercholesterolemia (HEFH) Management Market?

Rising Clinical Studies and Trials to boost Regional Demand

North America is predicted to hold the dominant market share of 41% revenue share in 2023 and is the fastest-growing market for Heterozygous Familial Hypercholesterolemia (HEFH) management, with a dominant 15.3% CAGR from 2023 to 2033. Growth can be attributed to the increasing research and developments by the key players in this region. At the same time, the huge number of clinical trials and studies being conducted on heterozygous familial hypercholesterolemia for the proper treatment are also accelerating the demand in the regional market.

For example, Ionis Pharmaceuticals, Inc., a pioneer in antisense therapeutics, and its collaborator AstraZeneca announced in 2022 that the ETESIAN Phase 2b study of ION449 (AZD8233), an investigational antisense drug intended to lower blood cholesterol levels in people with hypercholesterolemia by trying to target proprotein convertase subtilisin/kexin type 9 in mice, had shown positive results (PCSK9). The 71st Annual Scientific Session & Expo of the American College of Cardiology featured the presentation of these results.

The goal of the ETESIAN Phase 2b research was to evaluate ION449's effectiveness, safety, and tolerability in individuals with high-risk hypercholesterolemia. The study's primary goal of lowering blood LDL-C levels by up to 79% was achieved. Hence, there would be a lot of scope for North American manufacturers to develop in this market during the forecast period.

What can be expected from the European market for Heterozygous Familial Hypercholesterolemia (HEFH) Management?

Increasing Treatment Options and Innovations to augment Treatment Incidences

During the forecast period, the European market for Heterozygous Familial Hypercholesterolemia (HEFH) management is expected to garner a steady CAGR of 14%. But at the time, the European market for the management of heterozygous familial hypercholesterolemia (HEFH) is expected to witness this market gain of 31% in 2023. Expanding research and innovations by the key players and various projects being approved for the management of Heterozygous Familial Hypercholesterolemia and increasing authorizations of the clinical trials by some prominent companies in the region are propelling the growth.

Verve Therapeutics, Inc., a clinical-stage biopharmaceutical company that is developing single-course gene editing drugs to treat cardiovascular disease, declared in 2022 that the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) had approved its Clinical Trial Authorization (CTA) application for VERVE-101 as a prospective treatment for people with heterozygous familial hypercholesterolemia (HeFH). HeFH is a common hereditary variant of atherosclerotic cardiovascular disease (ASCVD) that can be fatal and is characterized by abnormally high blood levels of the disease-causing lipid LDL-cholesterol (LDL-C). Such developments are expected to accelerate the growth in the market from 2023 to 2033.

MarketNage
Become a MarketNgage Insider

A unified Market Research Subscription Platform, built for today's disparate research needs.

Category-wise Insights

By Product Type, which Category is expected to gain Maximum Traction?

ST-103-based Drugs to be Most Preferred Treatment Option

Over the course of the forecast period, ST-103-based drugs are anticipated to occupy a significant share of treating heterozygous familial hypercholesterolemia. In 2023, this category is anticipated to dominate with a 32% revenue share.

ST-103 is a popular statin. Since statins are advised for use in the therapy of hypercholesterolemia because of their safety and efficacy, it has been concluded that they constitute a substantial revenue generator among the market segments evaluated. Statins are the most popular treatment for hypercholesterolemia because they totally block the enzyme HMG-CoA reductase, which is in charge of producing cholesterol.

In addition, statins are engaged in lowering LDL cholesterol levels and raising HDL cholesterol levels. Such factors are expected to accelerate the growth prospects for Heterozygous Familial Hypercholesterolemia (HEFH) management from 2023 to 2033.

Start-up Scenario

The start-ups strive to set their goods apart on the global market by incorporating cutting-edge technology and enhanced safety measures. The symptoms are being treated first, of course, and also various metrics are being measured to check the present condition of the patient. Some of the companies are:

  • An Indian firm called Phable creates a telemedicine platform for managing chronic diseases. Patients may contact doctors on demand for treatment of diabetes, heart issues, and cancer through the startup's smartphone app. Additionally, it provides a marketplace where users may purchase Internet of Things (IoT) medical equipment for monitoring vital signs. The app integrates the data from various gadgets and regularly informs doctors about your health. Because of this, they are able to proactively identify patients' health problems in order to ensure prompt treatments and avoid hospital (re-)admissions.

Competitive Landscape

Some of the prominent players in the global market for heterozygous familial hypercholesterolemia (HEFH) management are:

  • Sanofi SA
  • Amgen Inc.
  • Novartis International AG
  • AdooQ Bioscience
  • Thermo Fisher Scientific
  • Universal Biologicals
  • Selleck Chemicals
  • Madrigal Pharmaceuticals
  • ShangHai Caerulum Pharma Discovery Co., Ltd.
  • Wuhan Biocar Pharmacy

Some of the prominent developments of the key players in the market are:

  • Novartis announced in 2021 that the US Food and Drug Administration (FDA) had approved Leqvio® (inclisiran), the world's first and only small interfering RNA (siRNA) medication to reduce low-density lipoprotein cholesterol (known colloquially as bad cholesterol or LDL-C) with 2 doses per year, after an initial dosage and one at three months. Leqvio is a ground-breaking strategy to reduce LDL-C and opens up new avenues as to how healthcare systems might influence cardiovascular disease, which is the most important public health issue of our day. They now have the chance to offer this first-ever authorized LDL-C-lowering siRNA-based treatment to combat ASCVD at scale throughout the United States in collaboration with partners.
  • In the US, Leqvio is prescribed to people with symptomatic atherosclerotic cardiovascular disease (ASCVD) and heterozygous familial hypercholesterolemia (HeFH) who need further LDL-C reduction in combination with diet and maximally tolerated statin medication. In ongoing clinical studies, the impact of Leqvio on cardiovascular mortality and morbidity is being investigated.

Report Scope

Report Attribute

Details

Market Value in 2023

US$ 15.11 Billion

Market Value in 2033

US$ 58.54 Billion

Growth Rate

CAGR of 14.5% from 2023 to 2033

Base Year for Estimation

2022

Historical Data

2018 to 2022

Forecast Period

2023 to 2033

Quantitative Units

Revenue in US$ Billion and CAGR from 2023 to 2033

Report Coverage

Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis

Segments Covered

  • Product Type
  • Application
  • Region

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa

Key Countries Profiled

  • USA
  • Canada
  • Brazil
  • Mexico
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • China
  • Japan
  • South Korea
  • Thailand
  • Singapore
  • Indonesia
  • Australia
  • New Zealand
  • GCC Countries
  • South Africa
  • Israel

Key Companies Profiled

  • Sanofi SA
  • Amgen Inc.
  • Novartis International AG
  • AdooQ Bioscience
  • Thermo Fisher Scientific
  • Universal Biologicals
  • Selleck Chemicals
  • Madrigal Pharmaceuticals
  • Shanghai Caerulum Pharma Discovery Co., Ltd.
  • Wuhan Biocar Pharmacy

Customization

Available Upon Request

Key Segments Covered in the Heterozygous Familial Hypercholesterolemia (HEFH) Management Market Report

By Product Type:

  • Gemcabene Calcium
  • MGL-3196
  • ST-103
  • Others

By Application:

  • Hospitals
  • Medical Centers
  • Clinics
  • Others

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa (MEA)

Frequently Asked Questions

From 2018 to 2022, the heterozygous familial hypercholesterolemia (HEFH) management market grew at a CAGR of 9.2%.

The heterozygous familial hypercholesterolemia (HEFH) management market is predicted to rise at a 14.5% CAGR from 2023 to 2033

The global heterozygous familial hypercholesterolemia (HEFH) management market is currently worth more than US$ 13.2 Billion.

By 2033, HEFH management market value is expected to reach US$ 58.54 Billion, as per Future Market Insights

In 2023, the ST-103 by product type is anticipated to dominate with a 32% revenue share.

Hospitals will likely account for 21% of all HEFH management procedures in 2023

The Europe HEFH management market is expected to grow with a steady CAGR of 14% until 2033

Table of Content

1. Executive Summary | Heterozygous Familial Hypercholesterolemia (HEFH) Management Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Product Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product Type, 2023 to 2033

        5.3.1. Gemcabene Calcium

        5.3.2. MGL-3196

        5.3.3. ST-103

        5.3.4. Others

    5.4. Y-o-Y Growth Trend Analysis By Product Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Product Type, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Application, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2023 to 2033

        6.3.1. Hospitals

        6.3.2. Medical Centres

        6.3.3. Clinics

        6.3.4. Others

    6.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Europe

        7.3.4. Asia Pacific

        7.3.5. Middle East and Africa(MEA)

    7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        8.2.1. By Country

            8.2.1.1. USA

            8.2.1.2. Canada

        8.2.2. By Product Type

        8.2.3. By Application

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Product Type

        8.3.3. By Application

    8.4. Key Takeaways

9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Product Type

        9.2.3. By Application

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Product Type

        9.3.3. By Application

    9.4. Key Takeaways

10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. United Kingdom

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Europe

        10.2.2. By Product Type

        10.2.3. By Application

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Product Type

        10.3.3. By Application

    10.4. Key Takeaways

11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. China

            11.2.1.2. Japan

            11.2.1.3. South Korea

            11.2.1.4. Singapore

            11.2.1.5. Thailand

            11.2.1.6. Indonesia

            11.2.1.7. Australia

            11.2.1.8. New Zealand

            11.2.1.9. Rest of Asia Pacific

        11.2.2. By Product Type

        11.2.3. By Application

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Product Type

        11.3.3. By Application

    11.4. Key Takeaways

12. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. GCC Countries

            12.2.1.2. South Africa

            12.2.1.3. Israel

            12.2.1.4. Rest of Middle East and Africa(MEA)

        12.2.2. By Product Type

        12.2.3. By Application

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Product Type

        12.3.3. By Application

    12.4. Key Takeaways

13. Key Countries Market Analysis

    13.1. USA

        13.1.1. Pricing Analysis

        13.1.2. Market Share Analysis, 2022

            13.1.2.1. By Product Type

            13.1.2.2. By Application

    13.2. Canada

        13.2.1. Pricing Analysis

        13.2.2. Market Share Analysis, 2022

            13.2.2.1. By Product Type

            13.2.2.2. By Application

    13.3. Brazil

        13.3.1. Pricing Analysis

        13.3.2. Market Share Analysis, 2022

            13.3.2.1. By Product Type

            13.3.2.2. By Application

    13.4. Mexico

        13.4.1. Pricing Analysis

        13.4.2. Market Share Analysis, 2022

            13.4.2.1. By Product Type

            13.4.2.2. By Application

    13.5. Germany

        13.5.1. Pricing Analysis

        13.5.2. Market Share Analysis, 2022

            13.5.2.1. By Product Type

            13.5.2.2. By Application

    13.6. United Kingdom

        13.6.1. Pricing Analysis

        13.6.2. Market Share Analysis, 2022

            13.6.2.1. By Product Type

            13.6.2.2. By Application

    13.7. France

        13.7.1. Pricing Analysis

        13.7.2. Market Share Analysis, 2022

            13.7.2.1. By Product Type

            13.7.2.2. By Application

    13.8. Spain

        13.8.1. Pricing Analysis

        13.8.2. Market Share Analysis, 2022

            13.8.2.1. By Product Type

            13.8.2.2. By Application

    13.9. Italy

        13.9.1. Pricing Analysis

        13.9.2. Market Share Analysis, 2022

            13.9.2.1. By Product Type

            13.9.2.2. By Application

    13.10. China

        13.10.1. Pricing Analysis

        13.10.2. Market Share Analysis, 2022

            13.10.2.1. By Product Type

            13.10.2.2. By Application

    13.11. Japan

        13.11.1. Pricing Analysis

        13.11.2. Market Share Analysis, 2022

            13.11.2.1. By Product Type

            13.11.2.2. By Application

    13.12. South Korea

        13.12.1. Pricing Analysis

        13.12.2. Market Share Analysis, 2022

            13.12.2.1. By Product Type

            13.12.2.2. By Application

    13.13. Singapore

        13.13.1. Pricing Analysis

        13.13.2. Market Share Analysis, 2022

            13.13.2.1. By Product Type

            13.13.2.2. By Application

    13.14. Thailand

        13.14.1. Pricing Analysis

        13.14.2. Market Share Analysis, 2022

            13.14.2.1. By Product Type

            13.14.2.2. By Application

    13.15. Indonesia

        13.15.1. Pricing Analysis

        13.15.2. Market Share Analysis, 2022

            13.15.2.1. By Product Type

            13.15.2.2. By Application

    13.16. Australia

        13.16.1. Pricing Analysis

        13.16.2. Market Share Analysis, 2022

            13.16.2.1. By Product Type

            13.16.2.2. By Application

    13.17. New Zealand

        13.17.1. Pricing Analysis

        13.17.2. Market Share Analysis, 2022

            13.17.2.1. By Product Type

            13.17.2.2. By Application

    13.18. GCC Countries

        13.18.1. Pricing Analysis

        13.18.2. Market Share Analysis, 2022

            13.18.2.1. By Product Type

            13.18.2.2. By Application

    13.19. South Africa

        13.19.1. Pricing Analysis

        13.19.2. Market Share Analysis, 2022

            13.19.2.1. By Product Type

            13.19.2.2. By Application

    13.20. Israel

        13.20.1. Pricing Analysis

        13.20.2. Market Share Analysis, 2022

            13.20.2.1. By Product Type

            13.20.2.2. By Application

14. Market Structure Analysis

    14.1. Competition Dashboard

    14.2. Competition Benchmarking

    14.3. Market Share Analysis of Top Players

        14.3.1. By Regional

        14.3.2. By Product Type

        14.3.3. By Application

15. Competition Analysis

    15.1. Competition Deep Dive

        15.1.1. Sanofi SA

            15.1.1.1. Overview

            15.1.1.2. Product Portfolio

            15.1.1.3. Profitability by Market Segments

            15.1.1.4. Sales Footprint

            15.1.1.5. Strategy Overview

                15.1.1.5.1. Marketing Strategy

        15.1.2. Amgen Inc.

            15.1.2.1. Overview

            15.1.2.2. Product Portfolio

            15.1.2.3. Profitability by Market Segments

            15.1.2.4. Sales Footprint

            15.1.2.5. Strategy Overview

                15.1.2.5.1. Marketing Strategy

        15.1.3. Novartis International AG

            15.1.3.1. Overview

            15.1.3.2. Product Portfolio

            15.1.3.3. Profitability by Market Segments

            15.1.3.4. Sales Footprint

            15.1.3.5. Strategy Overview

                15.1.3.5.1. Marketing Strategy

        15.1.4. AdooQ Bioscience

            15.1.4.1. Overview

            15.1.4.2. Product Portfolio

            15.1.4.3. Profitability by Market Segments

            15.1.4.4. Sales Footprint

            15.1.4.5. Strategy Overview

                15.1.4.5.1. Marketing Strategy

        15.1.5. Thermo Fisher Scientific

            15.1.5.1. Overview

            15.1.5.2. Product Portfolio

            15.1.5.3. Profitability by Market Segments

            15.1.5.4. Sales Footprint

            15.1.5.5. Strategy Overview

                15.1.5.5.1. Marketing Strategy

        15.1.6. Universal Biologicals

            15.1.6.1. Overview

            15.1.6.2. Product Portfolio

            15.1.6.3. Profitability by Market Segments

            15.1.6.4. Sales Footprint

            15.1.6.5. Strategy Overview

                15.1.6.5.1. Marketing Strategy

        15.1.7. Selleck Chemicals

            15.1.7.1. Overview

            15.1.7.2. Product Portfolio

            15.1.7.3. Profitability by Market Segments

            15.1.7.4. Sales Footprint

            15.1.7.5. Strategy Overview

                15.1.7.5.1. Marketing Strategy

        15.1.8. Madrigal Pharmaceuticals

            15.1.8.1. Overview

            15.1.8.2. Product Portfolio

            15.1.8.3. Profitability by Market Segments

            15.1.8.4. Sales Footprint

            15.1.8.5. Strategy Overview

                15.1.8.5.1. Marketing Strategy

        15.1.9. ShangHai Caerulum Pharma Discovery Co., Ltd.

            15.1.9.1. Overview

            15.1.9.2. Product Portfolio

            15.1.9.3. Profitability by Market Segments

            15.1.9.4. Sales Footprint

            15.1.9.5. Strategy Overview

                15.1.9.5.1. Marketing Strategy

        15.1.10. Wuhan Biocar Pharmacy

            15.1.10.1. Overview

            15.1.10.2. Product Portfolio

            15.1.10.3. Profitability by Market Segments

            15.1.10.4. Sales Footprint

            15.1.10.5. Strategy Overview

                15.1.10.5.1. Marketing Strategy

16. Assumptions & Acronyms Used

17. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Product Type, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by Application, 2018 to 2033

Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Product Type, 2018 to 2033

Table 6: North America Market Value (US$ Million) Forecast by Application, 2018 to 2033

Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 8: Latin America Market Value (US$ Million) Forecast by Product Type, 2018 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by Application, 2018 to 2033

Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 11: Europe Market Value (US$ Million) Forecast by Product Type, 2018 to 2033

Table 12: Europe Market Value (US$ Million) Forecast by Application, 2018 to 2033

Table 13: Asia Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: Asia Pacific Market Value (US$ Million) Forecast by Product Type, 2018 to 2033

Table 15: Asia Pacific Market Value (US$ Million) Forecast by Application, 2018 to 2033

Table 16: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 17: MEA Market Value (US$ Million) Forecast by Product Type, 2018 to 2033

Table 18: MEA Market Value (US$ Million) Forecast by Application, 2018 to 2033

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Market Value (US$ Million) by Product Type, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by Application, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 7: Global Market Value (US$ Million) Analysis by Product Type, 2018 to 2033

Figure 8: Global Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033

Figure 9: Global Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033

Figure 10: Global Market Value (US$ Million) Analysis by Application, 2018 to 2033

Figure 11: Global Market Value Share (%) and BPS Analysis by Application, 2023 to 2033

Figure 12: Global Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033

Figure 13: Global Market Attractiveness by Product Type, 2023 to 2033

Figure 14: Global Market Attractiveness by Application, 2023 to 2033

Figure 15: Global Market Attractiveness by Region, 2023 to 2033

Figure 16: North America Market Value (US$ Million) by Product Type, 2023 to 2033

Figure 17: North America Market Value (US$ Million) by Application, 2023 to 2033

Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 22: North America Market Value (US$ Million) Analysis by Product Type, 2018 to 2033

Figure 23: North America Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033

Figure 24: North America Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by Application, 2018 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by Application, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033

Figure 28: North America Market Attractiveness by Product Type, 2023 to 2033

Figure 29: North America Market Attractiveness by Application, 2023 to 2033

Figure 30: North America Market Attractiveness by Country, 2023 to 2033

Figure 31: Latin America Market Value (US$ Million) by Product Type, 2023 to 2033

Figure 32: Latin America Market Value (US$ Million) by Application, 2023 to 2033

Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 37: Latin America Market Value (US$ Million) Analysis by Product Type, 2018 to 2033

Figure 38: Latin America Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033

Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033

Figure 40: Latin America Market Value (US$ Million) Analysis by Application, 2018 to 2033

Figure 41: Latin America Market Value Share (%) and BPS Analysis by Application, 2023 to 2033

Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033

Figure 43: Latin America Market Attractiveness by Product Type, 2023 to 2033

Figure 44: Latin America Market Attractiveness by Application, 2023 to 2033

Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 46: Europe Market Value (US$ Million) by Product Type, 2023 to 2033

Figure 47: Europe Market Value (US$ Million) by Application, 2023 to 2033

Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 52: Europe Market Value (US$ Million) Analysis by Product Type, 2018 to 2033

Figure 53: Europe Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033

Figure 54: Europe Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033

Figure 55: Europe Market Value (US$ Million) Analysis by Application, 2018 to 2033

Figure 56: Europe Market Value Share (%) and BPS Analysis by Application, 2023 to 2033

Figure 57: Europe Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033

Figure 58: Europe Market Attractiveness by Product Type, 2023 to 2033

Figure 59: Europe Market Attractiveness by Application, 2023 to 2033

Figure 60: Europe Market Attractiveness by Country, 2023 to 2033

Figure 61: Asia Pacific Market Value (US$ Million) by Product Type, 2023 to 2033

Figure 62: Asia Pacific Market Value (US$ Million) by Application, 2023 to 2033

Figure 63: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033

Figure 64: Asia Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 65: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 66: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 67: Asia Pacific Market Value (US$ Million) Analysis by Product Type, 2018 to 2033

Figure 68: Asia Pacific Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033

Figure 69: Asia Pacific Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033

Figure 70: Asia Pacific Market Value (US$ Million) Analysis by Application, 2018 to 2033

Figure 71: Asia Pacific Market Value Share (%) and BPS Analysis by Application, 2023 to 2033

Figure 72: Asia Pacific Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033

Figure 73: Asia Pacific Market Attractiveness by Product Type, 2023 to 2033

Figure 74: Asia Pacific Market Attractiveness by Application, 2023 to 2033

Figure 75: Asia Pacific Market Attractiveness by Country, 2023 to 2033

Figure 76: MEA Market Value (US$ Million) by Product Type, 2023 to 2033

Figure 77: MEA Market Value (US$ Million) by Application, 2023 to 2033

Figure 78: MEA Market Value (US$ Million) by Country, 2023 to 2033

Figure 79: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 80: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 81: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 82: MEA Market Value (US$ Million) Analysis by Product Type, 2018 to 2033

Figure 83: MEA Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033

Figure 84: MEA Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033

Figure 85: MEA Market Value (US$ Million) Analysis by Application, 2018 to 2033

Figure 86: MEA Market Value Share (%) and BPS Analysis by Application, 2023 to 2033

Figure 87: MEA Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033

Figure 88: MEA Market Attractiveness by Product Type, 2023 to 2033

Figure 89: MEA Market Attractiveness by Application, 2023 to 2033

Figure 90: MEA Market Attractiveness by Country, 2023 to 2033

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Cholesterol API Market

Published : August 2022

Healthcare

HDL Cholesterol Kits Market

Published : February 2022

Healthcare

Cholesterol Monitors Market

Published : November 2017

Healthcare

Cholesterol Medicine Market

Published : January 2017

Google translate

Heterozygous Familial Hypercholesterolemia (HEFH) Management Market